ZEO ScientifiX, Inc. (OTCQB: ZEOX) is a clinical-stage biopharmaceutical company located inside Nova Southeastern University’s Collaborative Center for Research in Davie, Florida. ZEO is principally focusing on the development of innovative biological therapeutics for the treatment of chronic diseases and the provision of related services. The Company’s proprietary products are derived from allogenic and autologous sources and are manufactured in an FDA-registered, cGMP compliant laboratory to retain the naturally occurring bioactive exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent.
Company profile
Ticker
ZEOX
Exchange
Website
CEO
Manuel E. Iglesias
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
KEMPHARM INC, KEMPHARM, INC
SEC CIK
Corporate docs
Subsidiaries
ANU Life Sciences, Inc. • BD Source and Distribution Corp. • Beyond Cells Corp. • Ethan New York, Inc. • General Surgical Florida, Inc. • Mint Organics, Inc. • Mint Organics Florida, Inc. • Livin Again Inc. ...
ZEOX stock data
Latest filings (excl ownership)
8-K
Other Events
20 Sep 24
10-Q
2024 Q3
Quarterly report
16 Sep 24
8-K
Unregistered Sales of Equity Securities
7 Aug 24
D
$500.00 k in equity / options / securities to be acquired, sold $500.00 k, 1 investor
15 Jul 24
8-K
Unregistered Sales of Equity Securities
12 Jul 24
10-Q
2024 Q2
Quarterly report
14 Jun 24
8-K
Departure of Directors or Certain Officers
3 Jun 24
8-K
Departure of Directors or Certain Officers
2 Apr 24
10-Q
2024 Q1
Quarterly report
18 Mar 24
8-K
Other Events
4 Mar 24
Latest ownership filings
4
Change in insider ownership
3 Sep 24
SC 13G
Kompothecras Gary
12 Aug 24
4
Wendy Grey
15 Jul 24
4
Leathem S Stearn
15 Jul 24
4
Change in insider ownership
15 Jul 24
4
George Craig Shapiro
15 Jul 24
4
STEVEN JERRY GLAUSER
15 Jul 24
4
Charles Luther Bretz
15 Jul 24
4
IAN T BOTHWELL
15 Jul 24
4
Gurvinder Pal Singh
2 Apr 24
Financial summary
Quarter (USD) | Jul 24 | Apr 24 | Jan 24 | Oct 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Oct 23 | Oct 22 | Oct 21 | Oct 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.11 mm | 1.11 mm | 1.11 mm | 1.11 mm | 1.11 mm | 1.11 mm |
Cash burn (monthly) | (no burn) | (no burn) | 389.33 k | 427.08 k | 31.33 k | 71.94 k |
Cash used (since last report) | n/a | n/a | 727.89 k | 798.47 k | 58.58 k | 134.50 k |
Cash remaining | n/a | n/a | 377.11 k | 306.53 k | 1.05 mm | 970.50 k |
Runway (months of cash) | n/a | n/a | 1.0 | 0.7 | 33.4 | 13.5 |
Institutional ownership, Q3 2022
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 3 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 10.98 mm |
Total shares | 450.00 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Greyt Ventures | 200.00 mm | $4.70 mm |
Skycrest | 200.00 mm | $5.10 mm |
Modi Bhupendra Kumar | 50.00 mm | $1.18 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Sep 24 | Skycrest | Common Stock | Buy | Acquire P | No | No | 2.2 | 9,000 | 19.80 k | 268,604 |
30 Aug 24 | Skycrest | Common Stock | Buy | Acquire P | No | No | 2.2 | 1,000 | 2.20 k | 259,604 |
11 Jul 24 | Shapiro George Craig | Stock Options Common Stock | Grant | Acquire A | No | No | 2.35 | 125,000 | 293.75 k | 125,000 |
11 Jul 24 | Steven Jerry Glauser | Stock Options Common Stock | Grant | Acquire A | No | No | 2.35 | 125,000 | 293.75 k | 125,000 |
11 Jul 24 | Charles Luther Bretz | Stock Options Common Stock | Grant | Acquire A | No | No | 2.35 | 50,000 | 117.50 k | 50,000 |
11 Jul 24 | Bothwell Ian T | Stock Options Common Stock | Grant | Acquire A | No | No | 2.35 | 125,000 | 293.75 k | 125,000 |